Involvement of splenic iron accumulation in the development of nonalcoholic steatohepatitis in Tsumura Suzuki Obese Diabetes mice

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Murotomi, Kazutoshi ^a   Arai, Shigeyuki ^b   Uchida, Satoko ^b   Endo, Shin ^b   Mitsuzumi, Hitoshi ^b   Tabei, Yosuke ^a   Yoshida, Yasukazu ^a   Nakajima, Yoshihiro ^a  

^a NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^b HAYASHIBARA BIOCHEMICAL LABORATORIES INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IRON;

ANIMAL; COMPLICATION; DISEASE MODEL; EXPERIMENTAL DIABETES MELLITUS; LIVER; METABOLISM; MOUSE; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOLOGY; SPLEEN;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; IRON; LIVER; MICE; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; SPLEEN;

EID: 84960154064     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep22476     Document Type: Article

References (31)

1. Takahashi, Y., Sugimoto, K., Inui, H. & Fukusato, T. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 21, 3777-3785 (2015).
2. McCullough, A. J. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 34, 255-262 (2002).
3. Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313-1321 (2005).
4. Day, C. P. & James, O. F. Steatohepatitis: a tale of two "hits"? Gastroenterology 114, 842-845 (1998).
5. Cohen, J. C., Horton, J. D. & Hobbs, H. H. Human fatty liver disease: old questions and new insights. Science 332, 1519-1523 (2011).
6. Liu, J., Xu, Y., Hu, Y. & Wang, G. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy. Metabolism 64, 380-390 (2015).
7. Takaki, A., Kawai, D. & Yamamoto, K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int J Mol Sci 14, 20704-20728 (2013).
8. Tilg, H. & Moschen, A. R. Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits Hypothesis. Hepatology 52, 1836-1846 (2010).
9. Chitturi, S. et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: A manifestation of lipotoxicity? Hepatology 36, 403-409 (2002).
10. Buechler, C., Wanninger, J. & Neumeier, M. Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol 17, 2801-2811 (2011).
11. 2(15)O and a dynamic state method: 2). Ann Nucl Med 7, 251-255 (1993).
12. Tsushima, Y. & Endo, K. Spleen enlargement in patients with nonalcoholic fatty liver-Correlation between degree of fatty infiltration in liver and size of spleen. Dig Dis Sci 45, 196-200 (2000).
13. Tarantino, G. et al. Could inflammatory markers help diagnose nonalcoholic steatohepatitis? Eur J Gastroenterol Hepatol 21, 504-511 (2009).
14. Suzuki, K. et al. Measurement of spleen volume is useful for distinguishing between simple steatosis and early-stage non-alcoholic steatohepatitis. Hepatol Res 40, 693-700 (2010).
15. Nishida, T. et al. Spontaneous onset of nonalcoholic steatohepatitis and hepatocellular carcinoma in a mouse model of metabolic syndrome. Lab Invest 93, 230-241 (2013).
16. Mitsuzumi, H., Yasuda-Yamashita, A., Arai, N., Sadakiyo, T. & Kubota, M. Glucosyl Hesperidin Lowers Serum Triglyceride Level in the Rats Fed a High-Fat Diet through the Reduction of Hepatic Triglyceride and Cholesteryl Ester Japanese Pharmacology & Therapeutics 39, 13 (2011).
17. Miwa, Y. et al. Effects of glucosyl hesperidin on serum lipids in hyperlipidemic subjects: preferential reduction in elevated serum triglyceride level. J Nutr Sci Vitaminol (Tokyo) 50, 211-218 (2004).
18. Nelson, J. E. et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology 53, 448-457 (2011).
19. Chitturi, S. et al. HFE mutations, hepatic iron, and fibrosis: Ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 36, 142-149 (2002).
20. Sadrzadeh, S. M., Graf, E., Panter, S. S., Hallaway, P. E. & Eaton, J. W. Hemoglobin. A biologic fenton reagent. J Biol Chem 259, 14354-14356 (1984).
21. Tan, T. C. et al. Excess iron modulates endoplasmic reticulum stress-associated pathways in a mouse model of alcohol and high-fat diet-induced liver injury. Lab Invest 93, 1295-1312 (2013).
22. Elshazly, S. M. & Mahmoud, A. A. Antifibrotic activity of hesperidin against dimethylnitrosamine-induced liver fibrosis in rats. Naunyn Schmiedebergs Arch Pharmacol 387, 559-567 (2014).
23. Pari, L. & Shagirtha, K. Hesperetin protects against oxidative stress related hepatic dysfunction by cadmium in rats. Exp Toxicol Pathol 64, 513-520 (2012).
24. Tarantino, G., Scalera, A. & Finelli, C. Liver-spleen axis: intersection between immunity, infections and metabolism. World J Gastroenterol 19, 3534-3542 (2013).
25. Imeryuz, N. et al. Iron preloading aggravates nutritional steatohepatitis in rats by increasing apoptotic cell death. J Hepatol 47, 851-859 (2007).
26. Valenti, L. et al. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 138, 905-912 (2010).
27. Pari, L., Karthikeyan, A., Karthika, P. & Rahinam, A. Protective effects of hesperidin on oxidative stress, dyslipidaemia and histological changes in iron-induced hepatic and renal toxicity in rats. Toxicol Rep 2, 46-55 (2015).
28. Pradeep, K., Park, S. H. & Ko, K. C. Hesperidin a flavanoglycone protects against gamma-irradiation induced hepatocellular damage and oxidative stress in Sprague-Dawley rats. Eur J Pharmacol 587, 273-280 (2008).
29. Pérez-Vargas, J. E., Zarco, N., Shibayama, M., Segovia, J. & Tsutsumi, V. & Muriel, P. Hesperidin prevents liver fibrosis in rats by decreasing the expression of nuclear factor-κ B, transforming growth factor-β and connective tissue growth factor. Pharmacology 94, 80-89 (2014).
30. Wang, X. et al. Effects of hesperidin on the progression of hypercholesterolemia and fatty liver induced by high-cholesterol diet in rats. J Pharmacoll Sci 117, 129-138 (2011).
31. Orr et al. Obesity alters adipose tissue macrophage iron content and tissue iron distribution. Diabetes 63, 421-432 (2014).